Divi's Laboratories Ltd. Q2 FY2024 results: revenue ₹1,909 crore, up 2.9% on the year
Divi's Laboratories Ltd. (DIVISLAB) reported consolidated revenue from operations of ₹1,909 crore for Q2 FY2024, the quarter ended 30 September 2023, up 2.9% on the same quarter a year earlier. Profit after tax was ₹348 crore, down 29.5% on the year, and earnings per share ₹13.11. The figures are the company's own, from the unaudited results it filed with NSE on 6 November 2023.
The quarter, against the one before and a year earlier
| Line | Q2 FY2024 | Quarter before | A year earlier | Change on the year |
|---|---|---|---|---|
| Revenue from operations | 1,909 | n/a | n/a | n/a |
| Other income | 86 | n/a | n/a | n/a |
| Total income | 1,995 | n/a | n/a | n/a |
| Cost of materials consumed | 711 | n/a | n/a | n/a |
| Purchases of stock-in-trade | 0 | n/a | n/a | n/a |
| Changes in inventories | 99 | n/a | n/a | n/a |
| Employee benefit expense | 266 | n/a | n/a | n/a |
| Finance costs | 1 | n/a | n/a | n/a |
| Depreciation, depletion and amortisation | 95 | n/a | n/a | n/a |
| Other expenses | 354 | n/a | n/a | n/a |
| Total expenses | 1,526 | n/a | n/a | n/a |
| Profit before exceptional items and tax | 469 | n/a | n/a | n/a |
| Exceptional items | 0 | n/a | n/a | n/a |
| Profit before tax | 469 | n/a | n/a | n/a |
| Current tax | 107 | n/a | n/a | n/a |
| Deferred tax | 14 | n/a | n/a | n/a |
| Total tax | 121 | n/a | n/a | n/a |
| Profit after tax | 348 | n/a | n/a | n/a |
| Attributable to owners of the parent | 348 | n/a | n/a | n/a |
| Other comprehensive income | 1 | n/a | n/a | n/a |
| Total comprehensive income | 349 | n/a | n/a | n/a |
| EPS, basic | ₹13.11 | n/a | n/a | n/a |
| EPS, diluted | ₹13.11 | n/a | n/a | n/a |
₹ crore except per share.
Quarterly results, the last 12 quarters
| Q2 FY2024 | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,909 | 1,855 | 2,303 | 2,118 | 2,338 | 2,319 | 2,585 | 2,410 | 2,715 | 2,604 | 2,831 | 3,080 |
| Expenses | 1,526 | 1,461 | 1,669 | 1,593 | 1,722 | 1,675 | 1,807 | 1,796 | 1,948 | 1,838 | 2,023 | 1,964 |
| Operating profit | 479 | 489 | 731 | 622 | 716 | 743 | 886 | 729 | 888 | 890 | 934 | 1,255 |
| OPM % | 25% | 26% | 32% | 29% | 31% | 32% | 34% | 30% | 33% | 34% | 33% | 41% |
| Other income | 86 | 95 | 79 | 79 | 106 | 82 | 86 | 119 | 145 | 88 | 155 | 64 |
| Interest | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 3 | 8 | 6 | 6 | 6 |
| Depreciation | 95 | 95 | 95 | 97 | 99 | 99 | 107 | 112 | 113 | 118 | 120 | 133 |
| Exceptional items | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -74 | 0 | 0 |
| Profit before tax | 469 | 489 | 713 | 604 | 722 | 726 | 864 | 733 | 912 | 780 | 963 | 1,180 |
| Tax % | 26% | 27% | 25% | 29% | 29% | 19% | 23% | 26% | 24% | 25% | 22% | 24% |
| Net profit | 348 | 358 | 538 | 430 | 510 | 589 | 662 | 545 | 689 | 583 | 751 | 902 |
| EPS in ₹ | ₹13.11 | ₹13.50 | ₹20.25 | ₹16.20 | ₹19.20 | ₹22.20 | ₹24.93 | ₹20.49 | ₹25.97 | ₹21.98 | ₹28.31 | ₹33.95 |
| Filing | NSE | NSE | NSE | NSE | NSE | NSE | Filing | Filing | Filing | Filing | Filing | Filing |
₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company.
Source
Unaudited consolidated results for the quarter ended 30 September 2023, filed with NSE on 6 November 2023: the result statement. All of Divi's Laboratories Ltd.'s results: NSE company page.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.